Patient Recruitment Case Study – COVID-19 Vaccine
ClinicalConnection’s Pivotal Role during the COVID-19 Pandemic Enabled Vaccine Developer to Speed Data Submission to Global Regulators for its COVID-19 mRNA Vaccine in Adolescents
More than a year after a cluster of people in China’s Wuhan Hubei Province first experienced symptoms of a novel coronavirus that would become known as COVID-19, a major vaccine developer had only tested its mRNA vaccine in adults. Securing FDA authorization to inoculate adolescents against COVID-19 became an imperative. During 2020, more than two million minors are known to have contracted the virus. Although most cases in this age group were mild, they fueled the spread of the potentially deadly virus and contributed immeasurably to the disruption in our nation’s schools.
The sponsor quickly launched a Phase 2/3 clinical trial to test the safety and efficacy of the company’s vaccine in the adolescent cohort ages 12 to 17.
ClinicalConnection.com provides a patient recruiting clinical trials platform designed to help the clinical trials industry meet enrollment goals for research studies. ClinicalConnection.com has listed over 40,000 clinical trials in the U.S. and worldwide and referred more than one million participants to clinical research studies.